All News

With the delay in ICD-10, many insurers now have to slow down a mammoth IT project and, potentially more disruptive, make adjustments to a whole slew of programs and contracts.

Medicaid-financed emergency room costs statewide grew nearly $10 million to $178.3 million in fiscal year 2013.

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer, according to researchers.

Randomized trial to evaluate immune activation following treatment with immunotherapy combination. The open label design will allow for ongoing evaluation of clinical results from study.

Despite enrollment deadline extensions and expansion of the federal poverty guidelines, many uninsured Americans are choosing not to obtain health plans on insurance exchanges.

The U.S. Food and Drug Administration today approved the first FDA-approved HPV DNA test for women 25 and older that can be used alone to help a health care professional assess the need for a woman to undergo additional diagnostic testing for cervical cancer. The test also can provide information about the patient's risk for developing cervical cancer in the future.

Look beyond the EHR incentive program. A national effort to turn CMS's recent release of Medicare physician payment data into useful, actionable data visualizations is the hottest HIT challenge right now.

The expenses associated with cancer care in the United States are staggering and only expected to climb.

- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today that the United States Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee has voted to recommend against approval of Moxduo, an immediate release Dual Opioid® for the treatment of moderate to severe acute pain. The Advisory Committee found the Company did not provide sufficient evidence to warrant approval of Moxduo at this time.

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

Conference Coverage: AAAAI 2014

AJMC Panel Reviews Treatment, Cost Impacts of Emerging Shift to All-Oral Regimens With High Cure Rates

A blood test performed before radical cystectomy in patients with urothelial cancer of the bladder could identify the presence of circulating tumor cells (CTCs), which are predictive of outcome, according to a new study.

Initial sales of Sovaldi (sofosbuvir), Gilead's new drug for the treatment of hepatitis C virus infection (HCV), set a sales record in its first quarter on the market in the United States. In fact, Sovalidi outpaced the sales of any other drug in its class, netting $2.1 billion in revenue-or approximately $25 million per day.

People who go to Michigan hospitals seeking treatment for dental conditions that could have been prevented through regular dental care increase health care costs by millions of dollars in the state.

Leaders from the Centers for Medicare & Medicaid Services think private insurers have been too slow to adopt payment reforms, but they would be best served by adopting value-based payment systems in tandem with CMS today.

MicroRNA (miR)-21 has been revealed as an oncogene in cancer development, and is one of the miRNAs closely connected to angiogenesis. The authors aimed to explore the impact of miR-21 expression in both tumor and stromal compartments of non-small cell lung cancer (NSCLC), and correlations between miR-21 and angiogenic protein markers.